Who is sponsoring NCT01404013?

NCT01404013 is sponsored by The First Affiliated Hospital of Guangzhou Medical University.

What drugs are being tested in NCT01404013?

Interventions: ICS/LABA, Montelukast, ICS/LABA and Montelukast.

What is the status of NCT01404013?

NCT01404013 is currently UNKNOWN.

Last reviewed 2014-07-11 · How we verify

Randomised, Open-label, Parallel-group Study of Therapeutic Effect of Leukotriene Modulator Montelukast Alone or Combined With Inhaled Corticosteroid on Cough Variant Asthma

NCT01404013 Phase 4 UNKNOWN

This study aims to observe the therapeutic effect of leukotriene modulator montelukast alone or combined with inhaled corticosteroid(ICS) on cough variant asthma(CVA). The investigators hypothesize: 1. Cough score and cough reflex sensitivity will be improved after treatment with montelukast, inhaled corticosteroid/β2 agonist(ICS/LABA), and two combinations. 2. Combination of leukotriene modulator and inhaled corticosteroid/β2 agonist may have better efficacy when compared to montelukast, corticosteroid/β2 agonist alone while MON, is comparable to symbicort.

Details

Lead sponsor	The First Affiliated Hospital of Guangzhou Medical University
Phase	Phase 4
Status	UNKNOWN
Enrolment	99
Start date	2012-02
Completion	2014-08

Conditions

Asthma

Interventions

ICS/LABA
Montelukast
ICS/LABA and Montelukast

Primary outcomes

Day-time and night-time cough symptom total-score changes from baseline to visit 4 — 8 weeks

Countries

China